ArticleQuantitative imaging in medicine and surgery2026
Respiratory motion-corrected quiescent period gating magnetic resonance attenuation correction (Q.MRAC) for enhancing quantitative accuracy in hepatic [18F]FDG PET/MRI: a dual-domain motion compensation study.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory motion-induced misalignment between positron emission tomography (PET) and magnetic resonance attenuation maps remains a critical challenge in abdominal PET/magnetic resonance imaging (PET/MRI) quantification. This study evaluated the performance of a novel dual-domain motion correction strategy combining emission-domain [quiescent phase gating PET acquisition (Q.Static)] and attenuation-domain [quiescent period gating magnetic resonance attenuation correction (Q.MRAC)] approaches in enhancing standardized uptake value (SUV) accuracy in hepatic fluorine-18 fluorodeoxyglucose ([18F]FDG) imaging. Methods: Fifty patients underwent [18F]FDG PET/MRI with two respiratory motion correction protocols: dual-domain correction (Q.Static + Q.MRAC) and conventional MRAC [conventional static PET acquisition (Static) + conventional magnetic resonance attenuation correction (C.MRAC)]. Three 3-cm-diameter spherical volumes of interest (VOIs) were positioned in the right hepatic lobe, including the upper lobe (VOI1), middle lobe (VOI2), and lower lobe (VOI3) to evaluate SUV quantification, spatial alignment of attenuation maps against end-expiratory T2-weighted imaging (T2WI), and motion correction efficacy. Analysis of variance was applied for comparisons of the mean SUV (SUV Results: VOI2 demonstrated minimal SUV variability [coefficient of variation (CV) =2.29-2.55%], validating its use as a reference region as per the relevant guidelines. Respiratory motion caused consistent SUV underestimation: VOI1 underestimation relative to VOI2 was 16.4% for Q.Static + Q.MRAC and 26.3% for Static + C.MRAC, while the maximum underestimation rate for VOI3 was 11.4% for Static + C.MRAC. Q.Static + Q.MRAC reduced VOI1 underestimation by 38.9% as compared to Static + C.MRAC (P Conclusions: Dual-domain motion correction (Q.Static + Q.MRAC) significantly improves SUV quantification accuracy in the upper lobe of right liver. These findings establish a foundation for achieving greater accuracy for tumor assessment and metabolic imaging in clinical practice through the use of [18F]FDG PET/MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.